FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3042935384> ?p ?o ?g. }

• W3042935384 abstract "Abstract Background The standard therapy for patients suffering from sensorineural hearing loss is cochlear implantation. The insertion of the electrode array into the cochlea, with potential mechanical trauma and the presence of this foreign body inside the cochlea, may lead to free radical formation and reduced blood perfusion of the cochlea which can result in a loss of residual hearing. Studies have suggested that a particular combination of the antioxidants vitamins A, C and E as well as the vasodilator magnesium (together: ACEMg) may protect the residual hearing. Methods The potential protective effect of ACEMg on residual hearing preservation in cochlear implant (CI) patients was investigated in a single-centre, randomized, placebo-controlled, double-blind phase II clinical trial. CI candidates with some residual hearing in low frequencies receiving MED-EL implants of different FLEX electrode array lengths were treated with ACEMg tablets or placebo respectively 2 days preoperatively and up to 3 months postoperatively. The study objective was to demonstrate that ACEMg is more efficacious than placebo in preserving residual hearing during cochlear implantation by comparing the hearing loss (change in hearing thresholds at 500 Hz from baseline) 3 months after the first fitting between the two treatment groups and to investigate the treatments’ safety. Results Fifty-one patients were included in the study, which had to be terminated before the recruitment goal was reached because of IMP-resupply mismanagement of one partner. In the intention-to-treat population, 25 patients were treated with ACEMg and 24 patients with placebo. The mean hearing loss at 500 Hz was (± 15.84) 30.21 dB (placebo) or (± 17.56) 26.00 dB (ACEMg) 3 months after the initial fitting. Adjusting the postoperative hearing loss for the baseline residual hearing, planned electrode length and surgeon results in 8.01 dB reduced hearing loss in ACEMg-treated patients compared to placebo-treated ones. The safety analysis revealed that ACEMg was generally well-tolerated with adverse event frequencies below the placebo level. Conclusion This is the first clinical trial investigating a drug effect on residual hearing in CI patients. These first-in-man data may suggest that a perioperative oral administration of ACEMg is safe and may provide protection of residual hearing in CI patients. Trial registration EU Clinical Trial Register No. 2012-005002-22 . Registered on 6 December 2013. Funding: European Commission FP7-HEALTH-2012-INNOVATION-2." @default.
• W3042935384 created "2020-07-23" @default.
• W3042935384 creator A5008754990 @default.
• W3042935384 creator A5011213978 @default.
• W3042935384 creator A5036981246 @default.
• W3042935384 creator A5048224503 @default.
• W3042935384 creator A5071800169 @default.
• W3042935384 creator A5073259121 @default.
• W3042935384 creator A5081218445 @default.
• W3042935384 creator A5089009407 @default.
• W3042935384 creator A5090198629 @default.
• W3042935384 date "2020-07-14" @default.
• W3042935384 modified "2023-10-16" @default.
• W3042935384 title "Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients" @default.
• W3042935384 cites W1585823418 @default.
• W3042935384 cites W1966948918 @default.
• W3042935384 cites W1972649658 @default.
• W3042935384 cites W1975487046 @default.
• W3042935384 cites W1987447029 @default.
• W3042935384 cites W1998222160 @default.
• W3042935384 cites W2001456348 @default.
• W3042935384 cites W2013462552 @default.
• W3042935384 cites W2020372897 @default.
• W3042935384 cites W2027125450 @default.
• W3042935384 cites W2032018201 @default.
• W3042935384 cites W2043300436 @default.
• W3042935384 cites W2054107855 @default.
• W3042935384 cites W2086435353 @default.
• W3042935384 cites W2112118897 @default.
• W3042935384 cites W2204581710 @default.
• W3042935384 cites W2422062606 @default.
• W3042935384 cites W2515112438 @default.
• W3042935384 cites W2720576945 @default.
• W3042935384 cites W2724887241 @default.
• W3042935384 cites W2745521004 @default.
• W3042935384 cites W2765904780 @default.
• W3042935384 doi "https://doi.org/10.1186/s13063-020-04522-9" @default.
• W3042935384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7362557" @default.
• W3042935384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32665006" @default.
• W3042935384 hasPublicationYear "2020" @default.
• W3042935384 type Work @default.
• W3042935384 sameAs 3042935384 @default.
• W3042935384 citedByCount "9" @default.
• W3042935384 countsByYear W30429353842021 @default.
• W3042935384 countsByYear W30429353842022 @default.
• W3042935384 countsByYear W30429353842023 @default.
• W3042935384 crossrefType "journal-article" @default.
• W3042935384 hasAuthorship W3042935384A5008754990 @default.
• W3042935384 hasAuthorship W3042935384A5011213978 @default.
• W3042935384 hasAuthorship W3042935384A5036981246 @default.
• W3042935384 hasAuthorship W3042935384A5048224503 @default.
• W3042935384 hasAuthorship W3042935384A5071800169 @default.
• W3042935384 hasAuthorship W3042935384A5073259121 @default.
• W3042935384 hasAuthorship W3042935384A5081218445 @default.
• W3042935384 hasAuthorship W3042935384A5089009407 @default.
• W3042935384 hasAuthorship W3042935384A5090198629 @default.
• W3042935384 hasBestOaLocation W30429353841 @default.
• W3042935384 hasConcept C126322002 @default.
• W3042935384 hasConcept C141071460 @default.
• W3042935384 hasConcept C142724271 @default.
• W3042935384 hasConcept C168563851 @default.
• W3042935384 hasConcept C204787440 @default.
• W3042935384 hasConcept C27081682 @default.
• W3042935384 hasConcept C2778882171 @default.
• W3042935384 hasConcept C2780130748 @default.
• W3042935384 hasConcept C2780493683 @default.
• W3042935384 hasConcept C2780607864 @default.
• W3042935384 hasConcept C2908647359 @default.
• W3042935384 hasConcept C42219234 @default.
• W3042935384 hasConcept C535046627 @default.
• W3042935384 hasConcept C548259974 @default.
• W3042935384 hasConcept C71924100 @default.
• W3042935384 hasConcept C99454951 @default.
• W3042935384 hasConceptScore W3042935384C126322002 @default.
• W3042935384 hasConceptScore W3042935384C141071460 @default.
• W3042935384 hasConceptScore W3042935384C142724271 @default.
• W3042935384 hasConceptScore W3042935384C168563851 @default.
• W3042935384 hasConceptScore W3042935384C204787440 @default.
• W3042935384 hasConceptScore W3042935384C27081682 @default.
• W3042935384 hasConceptScore W3042935384C2778882171 @default.
• W3042935384 hasConceptScore W3042935384C2780130748 @default.
• W3042935384 hasConceptScore W3042935384C2780493683 @default.
• W3042935384 hasConceptScore W3042935384C2780607864 @default.
• W3042935384 hasConceptScore W3042935384C2908647359 @default.
• W3042935384 hasConceptScore W3042935384C42219234 @default.
• W3042935384 hasConceptScore W3042935384C535046627 @default.
• W3042935384 hasConceptScore W3042935384C548259974 @default.
• W3042935384 hasConceptScore W3042935384C71924100 @default.
• W3042935384 hasConceptScore W3042935384C99454951 @default.
• W3042935384 hasFunder F4320338377 @default.
• W3042935384 hasIssue "1" @default.
• W3042935384 hasLocation W30429353841 @default.
• W3042935384 hasLocation W30429353842 @default.
• W3042935384 hasLocation W30429353843 @default.
• W3042935384 hasLocation W30429353844 @default.
• W3042935384 hasOpenAccess W3042935384 @default.
• W3042935384 hasPrimaryLocation W30429353841 @default.
• W3042935384 hasRelatedWork W1568779642 @default.
• W3042935384 hasRelatedWork W1965917338 @default.
• W3042935384 hasRelatedWork W1991243515 @default.

• next